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Abstract 
 A common issue in cancer treatment is the lack of understanding of the heterogeneous 
chemical composition within individual tumors. It is known that several lipid bilayer 
extraction techniques allow molecular signals to be detected through microscopy as the tissue 
becomes less opaque. The goal of this project was to develop a method that could effectively 
remove lipid bilayer membranes from tissues. To accomplish this, a Supercritical Fluid 
Extraction (SFE) technique with supercritical CO2 was used to remove lipids from porcine 
tissue. The results compare the transparency level of tissue undergoing SFE before and after 
treatment. Given the data obtained in the experiments, it can be concluded that SFE using CO2 
has potential as a mechanism of lipid extraction for future verification of tumor heterogeneity.  
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Introduction  
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1.1 Background 
 
Cancer is known worldwide as one of the most deadly diseases, if not the deadliest, to 
affect humans. The toll that cancer has on human life is ever-increasing. In 2008, 
approximately 7.6 million people died because of cancer. It is expected that by 2015, 9 million 
people will perish from this condition [1]. Furthermore, cancer also brings an economical toll 
to those families whose members suffer from this condition. Many of the medicines currently 
used to treat cancer can rise above the $50,000 mark, over the course of the treatment. In fact, 
some drugs, such as Erbitux (a drug used to treat colorectal, head, and neck cancer), cost as 
high as $9600 per month [2]. Considering that oftentimes insurance companies do not offer 
their help to cover for complete costs, there is currently much work done to develop better 
techniques to treat cancer. 
In order to understand why cancer is such a costly disease, it is important to 
understand the pathways that lead to cancer and the effects that cancer has on the body. 
Cancer occurs when a cell’s DNA suffers significant damage and the cell does not repair the 
damage in its DNA. Under normal conditions, this damaged DNA, or mutation, would lead to 
DNA repair and/or cell apoptosis. Under cancer conditions however, the cell’s genome forces 
the normal cell to transform into a cancer cell, bringing forth a series of changes within the 
cell: increased and varied protein synthesis, abnormal growth, loss of function in the tissue 
and, in some cases, migration from the tissue. The causes of cancer may be categorized as 
either hereditary or carcinogenic [3]. When cancer is hereditary, a mutated gene in a person’s 
DNA is passed to future generations, effectively increasing the risk of cancer development in 
that person’s children. Carcinogens, such as certain types of radiation or chemical substances, 
can also affect DNA inside the cell. Once cancer cells have been transformed inside the body, a 
tumor is formed. Releasing hormones that alter tissue function and obstruct flow of 
substances causes damage to the tissue. When tumor cells detach themselves from the tumor, 
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metastasis occurs. In metastatic cancer, tumor cells have grown and developed sufficiently to 
travel to other parts of the body. A common example of cancer metastasis occurs in breast 
cancer. Breast cancer cells often travel to the lymph nodes located in the underarm, thus 
making treatment much more difficult because of the multiple locations of cancer cells in the 
body [4]. Additionally, cancer cells within a tumor do not have identical genetic identities, 
making cancer treatment the more difficult. Since cancer cells reproduce faster than normal 
cells, their genome very oftentimes undergoes rapid changes from generation to generation. 
This means that as a cancer cell reproduces, genetic variety in the offspring cells causes each 
cell to be different from each other. In more technical terms, each cancer cell derived from a 
single parent cell can produce its own set of its proteins and enzymes allowing each cell to 
have a different phenotype from other cells from their same generation. This difference in 
cancer cells within a single tumor is what is called tumor heterogeneity. Tumor heterogeneity 
is what makes cancer types differ so much from patient to patient. It is the reason why cancer 
treatments need to be often tailored to a single patient, since the biochemical properties 
inside that patient’s tumor are unique to his/her tumor. 
Knowing the variety in cancer types has allowed doctors and patients alike to treat 
cancer with a variety of methods. The most known methods involve the use of drugs to target 
cancer cells and either stop them from growing or kill them. This kind of drug treatment, 
known as chemotherapy, is widely used around the world as it offers close control of the drug 
being taken. However, control in chemotherapy does not always result in the desired outcome 
sine the patient’s response to the drug cannot be controlled. Many drugs have unknown 
adverse side-effects that vary from patient to patient [5]. These effects often result in painful 
side effects that effectively kill cancer cells while at the same time affecting normal cells in the 
patient’s body. Furthermore, the high cost of some of these drugs might imply that 
chemotherapy might not always prove to be the best way to treat cancer by itself. Other 
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effective cancer treatment methods such as radiation therapy and immunotherapy also focus 
on targeting the cancer cells specifically. At this point in time however, no method has proven 
to be 100% effective and infallible. There is a need to design novel methods to treat cancer 
that will allow a patient to receive harmless and effective treatment at the same time.  
The goal of this project is to create a method that will allow for a reliable and quick 
check of the protein composition of tumors in patients suffering from cancer. Given the 
current state of cancer treatment, along with the high cost associated with cancer, our team 
has identified an issue in the way treatment is performed in the modern days. Although 
methods such as chemotherapy and radiation therapy involve consideration of various factors 
inherent to the patient (such as weight, metabolism, blood count, past diseases), the majority 
of these methods often do not take into account the difference within the patient’s tumor. That 
is, tumor heterogeneity is not always a factor that many of the current cancer treatment 
methods take into account. Even though there exist programs, such as The Cancer Genome 
Atlas (TCGA), which attempt to categorize cancers in terms of genetic composition, there is no 
method that can actually identify tumor composition in a fast and effective manner [6]. 
However, there have been methods created in the recent years that provide an idea to 
perform protein labeling and protein visualization within a tumor. Methods such as 
immunoblotting and 3D fluorescence techniques allow for protein recognition and labeling 
[7]. Methods involving the use of chemical reagents and electrical leaching to remove lipids 
from cells allow for tissue to become almost transparent allowing for much easier 3D 
visualization [8 and 9]. These types of methods will provide the technical context for the 
development of the method in this project.    
To create such method, the project strategy to be employed will focus on developing a 
multi-step process that will allow clinicians to determine heterogeneity in tumors in a quick 
and effective manner. The strategy for this project is to begin looking at past experiments 
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related to tumor heterogeneity, cancer treatment, and protein labeling within transparent 
tissue. Once research on related techniques has been done, a process will be developed so that 
tumor tissue can be properly embedded into a scaffold. In the final design, it is intended to 
obtain tumor tissue from a tumor biopsy of a cancer patient. Once the tissue is in the scaffold, 
the lipid bilayer of the tumor cells will be removed. Without the lipid bilayer membrane, the 
tumor cells will allow visible light to go through them. This will then allow the visualization of 
proteins once these proteins have been fluorescently labeled. Proteins will then be identified 
by clinicians, and treatment strategies will be formulated based on the specific proteins found 
within the tumor.    
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2.1 Cancer Background 
 
Cancer is one of the most deadly conditions that affect the human body. In the US, 
cancer is the second most fatal disease behind heart failure. The toll of cancer is also heavy 
around the globe. In 2004, 7.4 million deaths were registered as being caused by cancer, this 
being a 12.6% of the total deaths estimated in that year [10]. Cancer is also one of the most 
troublesome diseases to treat because it is not caused by a particular condition and it is not 
location-specific. Cancer begins as the DNA inside a cell becomes damaged by one of the many 
pathways that lead to cancer. These pathways are referred to as carcinogens, and they can be 
either substances or radiation that damages the genetic composition of the cell. Cancer can 
also be a hereditary condition. Parents who have often suffered from cancer might end up 
having offspring who may develop the condition at any time during their lifetime. And since 
cancer is a disease that does not originate in the same part of the body for all patients, cancer 
has become a complex disease to treat once it has progressed inside the body.  
2.1.1 Carcinogenesis  
 
Cancer begins as a single cell in tissue becomes altered by an environmental or 
hereditary factor [11]. Environmental factors refer to any of those factors that are not 
genetically inherited. Factors such as chemicals, infections, and radiation can all be considered 
environmental since they can all cause DNA mutations. These factors, referred to as 
carcinogens, most often affect the cell’s DNA by damaging a particular gene that encodes 
against tumor initiation. For example, a particular gene known as TP53 is oftentimes 
inactivated by a protein created by the genetic code in the human papilloma virus (HPV). 
TP53 is a tumor suppressor gene that can regulate DNA repair proteins and initiate apoptosis 
in the cell in case DNA damage is severe [12]. Other carcinogens might affect gene function by 
forcing a gene to overexpress a particular protein that promotes cell growth or proliferation. 
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Such genes, known as proto-oncogenes, might become oncogenes, or genes that code for a 
protein that will initiate cancer. Contrary to environmental factors, hereditary factors are 
those that arise from hereditary conditions meaning that they are passed from parents to 
their offspring. Gene defects passed down from parents are very often the cause of hereditary 
cancers. In breast cancers for example, it is known that the inherited mutation in BRCA genes 
can lead to the development of cancer accounted for more than 75% of breast cancer cases 
[13]. 
Carcinogenesis, the term used to refer to the growth of cancer cells, occurs when 
either environmental or hereditary factors cause damage to the DNA of a single cell. Most of 
the time, a cell is capable of repairing the damage in its DNA. In other cases, if the damage is 
irreversible, the cell’s DNA triggers the production of proteins necessary for the cell to 
undergo apoptosis. Carcinogenesis happens when either of these pathways (DNA repair or 
cell apoptosis) fails to be executed properly. In many cases, the environmental carcinogens 
lead to a mutation in a specific gene in the DNA that can code for a repair protein. For 
example, ultraviolet radiation known as UVB can affect DNA by causing malfunctions of entire 
genes. UVB can cause single-strand damages in pyrimidine monomers (Figure 1), or double 
stranded breakage (Figure 2) which often accounts for deleted genes [14 and 15]. 
17 
 
 
Figure 1: Pyrimidine dimers [16]. 
 
Figure 2: Double strand breakage [17]. 
Hereditary factors lead to carcinogenesis as altered genes in parents are passed down 
to their children. In many cancers, inactivated tumor suppressor genes like the one coding for 
the APC protein (adenomatous polyposis coli), appear in the offspring genome. The APC gene 
codes for the APC protein which regulates cell growth, proliferation and movement of 
colorectal cells. In the cases of people who have inherited the inactivated APC gene, by the 
time they reach the age of 40, the probability of getting colorectal cancer is almost 100% [18].  
While inherited mutations in genes do not always lead straightly to carcinogenesis, other 
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pathologies might cause further mutations in the individual which can eventually trigger the 
carcinogenic pathway.  
2.1.2 Symptoms 
 
Once a cell has become a cancer cell, or transformed, the effects of this transformation 
are spread to the surrounding tissue. At the early stages of cancer, when the cell has just 
begun growth and early duplication, no apparent symptoms may be perceived by the patient. 
However, as the original cancer cell undergoes several rounds of duplication and the number 
of cancer cells increases, a tumor, or neoplasm, is formed. Neoplasms, which refer to the 
abnormal growth and accumulation of tissue, are often responsible for the earliest symptoms 
related to cancer. Many tumors, such as the ones that grow in the pancreas, cause no symptom 
until these tumors grow in size and begin to push against the nerve endings in the tissue. In 
other more sensitive organs however, tumors of the smallest of sizes might cause symptoms 
as soon as the organ’s functions become interrupted by the presence of the tumor. This is the 
case of tumors that grow in the brain or lung, where a slight disturbance in those organs 
might cause headaches or heavy coughing. In fact, most of the common symptoms associated 
to other common diseases include headaches, tiredness, fever, and weight loss. The more 
specific symptoms of tumor presence are always dependent on the location of the tumor. 
Examples of specific symptoms of cancer are: lump(s) in the body, strong cough or 
hoarseness, difficulty in swallowing, abnormal bleeding, difficulty in urinating, and changes in 
bowel movement. [19 and 20] 
As the cancer progresses, oftentimes cancer cells undergo a process known as 
metastasis. This refers to the cells acquiring the ability to de-attach from the tissue matrix that 
binds them to their tissue. Metastatic cancer cells are what make cancer so deadly. These cells 
usually de-attach from the tumor and travel through the vessels of the circulatory and 
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lymphatic system. As these metastatic cells move through the body, they end up settling in a 
body part different from the one they originated. As the metastatic cell settles and replicates 
in the new tissue, a new tumor will form in tissue different from the original. In cases where 
metastasis occurs, symptoms of metastasis only become apparent once a new tumor begins to 
form. In the majority of cases, metastasis is a signal of a very advanced stage of cancer. At a 
metastatic cancer stage, priority is given in pointing out the locations where cancer cells 
might have settled so that treatment can be given to the patient. Symptoms associated with 
tumor metastasis are often a replica of when cancer was first diagnosed, though with the 
added intensity of being a second (or even third) time. 
2.1.3 Costs  
 
The American Cancer Association (ACA) shows in their Global Facts and Figures that 
in 2004, about 7.4 million people died of cancer worldwide. It also shows that 5.2 million 
people out of those 7.4 million died in developing countries whereas the remaining 2.2 million 
died in developed countries. Out of the many diseases that claimed human lives in that year, 
such as HIV/AIDS, malaria, diabetes, and pulmonary diseases, cancer was the second deadliest 
disease behind heart failure. [21] 
20 
 
Figure 3: Worldwide causes of death in 2004[21]. 
 
 In the United States alone, 1,638,910 new cancer cases were reported in a 2012 ACA 
document. Out of all those cases, 577,190 people died of cancer in 2012, a 35% of the total 
1,638,910.  An estimated distribution of 52% male deaths against 48% female deaths also 
shows that cancer affects men and women similarly. [21] 
Aside from the human loss, financial loss is also great in the cancer treatment area. 
The ACA reports that in 2007, about $ 103.8 billion were invested in cancer care alone in the 
United States [21]. The National Cancer Institute reports that in 2010 about $124.5 billion 
were invested in cancer care, and that by 2020 it is expected that $158 billion (in 2010 
dollars) will be spent in cancer care [21]. In terms of single drugs or treatment, cancer is also 
one of the most expensive conditions to treat. Drugs such as Avastin can cost as high as 
$55,000 per year, whereas therapies such as proton therapy radiation can cost as high as 
$50,000 per session [22 and 23]. 
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2.1.4 Treatment 
 
As mentioned before, costs associated with cancer treatment are often very high. This 
is often the case because of the equipment and technology used to treat cancer patients. In 
many cases, a single individual must undergo a series of combined therapies that will try to 
minimize the effects of cancer on the patient. Most of the time these therapies target the 
cancer cells directly since these therapies attempt to kill these cells. Other therapies however, 
help the patient by identifying the size of the tumor in the patient and by minimizing the 
symptoms caused by cancer. [24] 
2.1.4.1 Chemotherapy 
 
Chemotherapy refers to the use of drugs to destroy cancer cells or to reduce the 
symptoms caused by cancer and other cancer therapies. Chemotherapy has been used since 
the early 1950’s to treat to cancer and has proved to be an effective therapy ever since [25]. 
Normally, the drugs used for chemotherapy attempt to damage the DNA in the cells in order to 
prevent growth and proliferation. The types of drugs used for chemotherapy include: 
alkylating agents, antimetabolites, anti-tumor antibiotics, enzyme inhibitors, and 
corticosteroids among others. Some of these drugs have major adverse side effects such as 
heart complications, secondary cancer, and peripheral nervous system damage. Since most of 
these drugs do not specifically target tumor cells, the normal cells that surround the tumor 
tissue might also be affected by the drug. [26].   
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Figure 4: Objectives of chemotherapy [27]. 
 
2.1.4.2 Radiation therapy 
 
Radiation therapy refers to the kind of treatment that involves the use of radiation to 
destroy cancer cells. The type of radiation used to treat cancer involves high doses of ionizing 
radiation such as x-ray or gamma rays. These rays are capable of damaging the DNA structure 
of cells so that they do not grow or reproduce. The types of radiation used against cancer are 
photon radiation and particle radiation. Photon radiation refers to the types of radiation 
which come from radioactive sources such as cobalt, cesium, or from a machine called linear 
accelerator. In photon radiation, the ions produced in the DNA atoms damage the structure of 
the double-stranded DNA. Particle radiation refers to the use of subatomic particles which 
cause damage to the cancer cells’ DNA. Electron beams, proton beams, neutron beams, and ion 
radiation are all examples of types of particle radiation. These types of radiation can be used 
for a variety of cancer types. Electron beams are mostly used to treat skin cancers since they 
do not penetrate deep in the body. Neutron beams and carbon ion radiation are stronger 
types of radiation that are used to attack cancer cells deep within tissue. Nonetheless, 
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radiation still poses a threat to the normal tissue surrounding the cancer cells, since radiation 
damages all cell’s DNA equally. [28 and 29] 
  
 
Figure 5: Example of the configuration of common radiation therapy in a clinic [30]. 
 
2.1.4.3 Surgery 
 
Surgery is mainly done in cancer in order to extract biopsies or tumors from the 
patient’s body. Surgery has some other applications which can help prevent cancer or 
diagnose the extent at which cancer has grown in the body. Some of the types of surgery are 
preventive surgery, diagnostic surgery, curative surgery, and debulking surgery. Preventive 
surgery as the name suggests, is used to prevent the formation of tumors by removing tissue 
which is very prone to becoming cancerous. Diagnostic surgery is used to extract a part of 
tumor tissue in order to identify the kind of cancer inside the patient’s body. Curative surgery 
and debulking surgery can be used to remove tumor from the patient to either attempt to cure 
or to reduce the size and effects of the tumor inside the body. [31] 
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2.1.4.4 Other methods 
 
Aside from the three most common methods used to treat cancer, there are other 
methods that can provide assistance in cancer treatment. Some of these methods are 
immunotherapy, photodynamic therapy, and targeted therapy. Immunotherapy is the use of 
the body’s own immune system to target and attack cancer cells. This is done by using 
antibodies or vaccines which can then help the body’s immune system target and destroy 
cancer cells once they start growing [32]. Photodynamic therapy uses specialized drugs, called 
photosensitizing agents, and light to kill cancer cells. These photosensitizing agents, once 
inside the cancer cells, kill cancer cells as they react with oxygen inside the cells after light has 
been applied on the tumor site. Targeted therapy is similar to chemotherapy in that it uses 
drugs to target cancer cells. Targeted therapy however, allows for these drugs to attack cancer 
cells while causing minor damage to the surrounding normal cells. [24]  
 
2.2 Tumor Heterogeneity 
 
Tumor heterogeneity refers to the biochemical variability that exists in single tumors 
in a cancer patient. Tumor differences exist in individual tumors because of the phenotype 
differences that cancer cells express within the tumor. Some of these differences include 
antigen expression, membrane composition, response to chemotherapy, and metastatic 
proclivity [33]. However, there are other views that refer to tumor heterogeneity as the 
difference in cell lineage that give rise to different types of cancer cells. Regardless of the point 
of view, tumor heterogeneity provides an important explanation of why current cancer 
treatment methods do not always provide a cure for cancer. 
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2.2.1 Causes and Effects  
 
There are many causes of tumor heterogeneity. One of the causes of tumor 
heterogeneity is believed to be related to the developmental changes that cancer cells 
undergo as they grow in tissue. Studies have shown that normal cells, prior to becoming 
cancer cells, are also heterogeneous among themselves [34]. The different carcinogen 
susceptibility of each cell may transform each cell differently, since some cells might not be 
directly affected by the carcinogen, but might still be altered genetically to be transformed 
later in their lifetime. It is believed that tumor specific mechanisms, such as genetic instability, 
are factors that lead to the cell heterogeneity within tumors [35].Since cancer cells are 
transformed when DNA in normal cells is damaged, further errors in the DNA may lead to 
different types of cancer cells being transformed. DNA mutations such as point mutations, 
genomic rearrangements, and gene deletions give rise to phenotypic variability of cancer cells 
that have originated from a single cancer cell. The evidence of this comes from observing the 
abnormalities of karyotypes in the development of fibrosarcoma (fibroblast-derived tumor) 
cells that appeared to have greater mutations when they became metastatic [36]. 
Furthermore, studies have also shown that both genetic and epigenetic mechanisms lead to 
activation of repressed genes in certain tumor subpopulations [37]. [38] 
Tumor heterogeneity causes variations in the growth rate, chemical production and 
sensitivity of cancer cells toward chemotherapy. The variation in growth was reported in 
study that shows how spontaneous mutations occurred mostly in metastatic subpopulations 
of fibrosarcoma cells [39]. Chemical production may also vary within single tumors because of 
the activation of repressed genes [37].The chemical production variability may a cause of the 
different levels of metastatic cancer cells in a tumor. This implies that for each different 
subpopulation of cancer cells, different genes coding for different proteins may be activated to 
support the metastatic path of the subpopulation. Chemical sensitivity of different 
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subpopulations of cancer cells has also been identified as a cause of tumor heterogeneity. This 
sensitivity has been identified to come before the transformation of cancer cells. Normal cells 
within tissue have different susceptibilities towards carcinogens, and as such it is believed 
that transformed cancer cells retain the characteristics of the normal cells that preceded them 
[40]. [38] 
 
2.2.2 Effects on Cancer Treatment 
 
Even though experiments that prove the existence of different subpopulations of cells 
in tumor are hard to come by, clinicians acknowledge the presence of these subpopulations. 
By accepting this idea, clinicians often provide explanations as to why certain drugs do not 
work well against a specific tumor. Tumor cell populations are believed to vary with respect 
to metastatic cell formation, meaning that they vary according to whether or not they can de-
attach from the tumor tissue. Several cancer treatments’ effectiveness are often stopped by 
the fact that metastasis has occurred in the patient. Since there are very few techniques 
currently available to study the composition of cancer cells while inside the tumor, clinicians 
often find themselves performing complicated and dangerous procedures in order to get rid of 
the metastasized cancer. Thus, there is a need to address tumor heterogeneity in order to 
identify the different kinds of cancer cell subpopulations that exist within a single tumor. 
 
2.3 Project Significance 
 
This project attempts to create a method that, in the long run, will allow clinicians to 
detect tumor heterogeneity in a fast way, by providing information of the biomolecules 
present within the tumors. Current techniques used in cancer treatment are very costly and 
do not offer a cure 100% of the times. Current techniques are also affected by the mentality of 
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“broad medicine” that many clinicians adopt when treating cancer patients suffering from the 
same cancer type. Thus, it has been decided that our project will allow clinicians to follow a 
personalized approach when treating patients that will let them construct cancer treatment 
roadmaps that will specifically focus on a single patient. 
 
2.3.1 Current Issues  
 
Even though cancer treatment nowadays may cause a significant improvement in 
cancer patients, it is true that adverse side effects and human errors often reduce the 
effectiveness of the cancer treatment. A study done at the University of Alabama at 
Birmingham provides valuable information on the amount of errors that happen in the clinical 
environment. The study found out that out of 20,979 patient encounters, 89 chemotherapy 
errors were made by the team treating the patients. Furthermore, it was found that the 
majority of these errors occurred due to the use of an incorrect drug or an incorrect dosage 
given to patient. The figure below shows the statistics obtained for this study:  
 
Figure 6: Results for the study done at UAB. This is the distribution of the 89 medication errors [41]. 
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Other issues that current cancer treatment methods have are the amount of adverse effects 
that the substances used cause to the cancer patients. Drugs such as Sprycel, used to treat 
leukemia, often have strong adverse side effects. Sprycel is known to cause pulmonary arterial 
hypertension, a condition that affects the heart and most often leads to heart failure. [42] 
 
2.3.2 Personalized Approach 
 
In order to address some of the issues that current cancer treatment methods cannot 
prevent, the method developed in this project is expected to help clinicians in following a 
personalized approach to treat cancer. There are not many technologies that allow 
visualization and identification of molecular composition of tumors. In order to perform 
personalized medicine, clinicians tend to rely on factors such the patients’ age, gender, family 
history. There are cases however in which more specific observations on the patients’ 
biochemistry lets clinicians make decisions. Taximofen, which is used to treat breast cancer, is 
used on patients who have estrogen receptor sensitivity and is not recommended to be used 
on patients who do not have such receptor. If any major technology allowed for the screening 
of the receptor’s presence, then the clinicians’ job would be greatly simplified.  Therefore, 
understanding complex biological systems is essential for clinicians since this allows them to 
prescribe apply treatments on cancer patients without the risk of adverse effects or wasted 
resources. [43] 
 
2.4 Technical Background 
 
This project will attempt to provide a more personalized approach during cancer 
treatment by making a sample tumor tissue transparent while also allowing visualization and 
identification of proteins within the tumor sample. By making the tumor tissue transparent, 
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we expect to reduce light scattering and increase the deep-tissue visualization of modern 
imaging techniques. Proteins are a focus of our project since we also expect to provide a 
method to preserve proteins within tumor samples. Identifying proteins and other 
biomolecules in sample tumor tissue coming from a patient can potentially allow clinicians to 
better make decisions when prescribing a treatment for the patient. Imaging of the tissue will 
provide the visualization necessary for the molecules in the molecule to be identified.  
 
2.4.1 Transparency  
 
Optically clearing tissue allows us to match the refractive index of tissue in order to 
better observe the components that lie within the tissue. Several studies serve as examples of 
the ways in which transparency allows for deep tissue imaging. CLARITY uses a method that 
extracts the lipid bilayer membrane from cells to render brain cells transparent so that the 
cells deep within the tissue can be labeled and observed in 3D. As this study shows, 
transparency is achieved once the lipid bilayer membranes of cells are removed. In this 
project, we will attempt to perform lipid bilayer extraction using a novel approach. [8] 
The lipid bilayer membrane is the outermost membrane that surrounds the human 
cells. Lipid bilayers are composed of phospholipids that arrange themselves in such a way that 
the hydrophobic ends are close to each other and the hydrophilic ends are on the outside and 
the inside of the cell. The lipid bilayer provides cells with structural integrity, molecular 
diffusion, and protection against hazardous molecules.  
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Figure 7: Lipid bilayer in human cells [44]. 
However, the lipid bilayer membrane is also responsible for light scattering when it 
comes to visualizing intracellular units. Studies show how light is scattered once it reaches the 
membrane of the cell, thus preventing for deep tissue imaging techniques to reach the inside 
of the cell. [45] 
 
Figure 8: Transmission fraction and Intensity values of light traveling through mouse brain cells with lipid bilayer 
membrane [45]. 
 
The figure above shows how the transmission fraction (which refers to the amount of 
light that can go through a material) decreases as the slice thickness of the brain tissue 
increases. Also, light intensity in non-sectioned tissue tends to decrease as the depth of tissue 
analysis increases. This only shows how lipid membranes in human cells prevent deep tissue 
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molecular phenotyping. Yet, results from studies like the one shown above provide support 
for the idea of lipid extraction via some mechanism. 
 
2.4.2 Proteins in Tumors 
 
To obtain information of the biochemical composition of tumors after rendering tissue 
transparent, it will be necessary to label and visualize the molecules that exist within the 
tumor. Proteins are widely known to be active tumor biomarkers, since overexpression of 
certain proteins in cancer patients allow clinicians to make decision as to what treatment 
should be followed. In fact most tumor biomarkers can be easily obtained by taking classic 
tests out of the patient, such as blood or urine samples. In other cases looking for specific 
proteins might allow to predict the course of action that a tumor will take. A study done by 
researchers of the National Institute of Health and the University of Hong Kong, indicated that 
cancer metastasis and growth could be well predicted by measuring the protein in tumors 
that were surgically removed. The specific protein looked at in this study was CPE- Δ N, which 
is believed to form in most cancer cells once they become metastatic. Thus, the researchers 
concluded that by quantifying the expression of the protein it is possible to prepare 
techniques that can refine treatment in metastatic cancers. [46 and 47]   
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Figure 9: Results obtained in the NIH experiment. Notice how at later stages of cancer, more CPE- Δ N is found to be 
present in tumors [47]. 
 
2.4.3 Imaging Proteins 
 
In order for clinicians to acknowledge the presence of a particular protein in a tumor, 
labeling and imaging techniques need to be used. It is necessary to be able to identify the 
proteins within the tissue. To do this, several methods can be performed to either directly 
identify proteins within tumors or to tag for fluorescent imaging. Some of the methods that 
are widely used to identify the presence of proteins are ELISA and immunoblotting. ELISA 
consists of determining if a particular protein exists within a sample. It is done by placing 
sample serum that has been centrifuged into the bottom of a 96-well plate. In this plate 
antibodies are placed on the serum containing the proteins which can then metabolize color 
on the wells. At the end of the procedure, optical density readings are taken to measure the 
amount of protein present in each well [48]. Immunoblotting consists in using gel 
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electrophoresis to separate proteins within a tissue extract by their 3D structure [49]. Besides 
identifying protein presence in tumors, labeling and imaging can be used to better visualize 
proteins within the tumor. By labeling proteins using specific fluorescent antibodies, it is 
possible to later use imaging methods such as 3D confocal microscopy or photon emission 
microscopy [50.]  
 
2.5 Related Methods 
 
2.5.1 The Cancer Genome Atlas  
 
 Currently, there are over two hundred distinct cancer types which are initiated by 
DNA errors which lead to uninhibited cell development. If the errors for each genome, its 
complete DNA set, could be monitored and studied, identifying what triggers the disease could 
be possible. This is a more personalized approach to studying cancer. The Cancer Genome 
Atlas is huge database of genome variations of cancer types and subtypes. This program was 
established by the National Institute of Health (NIH), The National Cancer Institute (NCI), and 
the National Human Genome Research Institute (NHGRI). Their goal is to create an atlas, a 
collection of maps, of specific cancer types. All of the data however, is open to the public. This 
allows researchers worldwide to contribute to this compilation and this data can also be used 
in research. Currently, over twenty types of human cancer has been studied and 
characterized. [6] 
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Figure 10:Circos Plot. Outer ring represents the chromosomes and Inner rings represent the locations of different 
types of mutations [6]. 
 The Cancer Genome Atlas (TCGA) focuses on four main areas: Tissue Processing, 
Research and Discovery, Data Sharing, and Community Research and Discovery. Tissue 
Processing is the initial step, where a sample of tumor tissue is donated. This sample is 
donated along with a sample of normal tissue, most often blood. These samples, called bio-
specimens, need to satisfy a strict set of standards so that the DNA and RNA can be used for 
analysis and sequencing. The department that handles this, the TCGA Biospecimen Core 
Resources, also eliminates any trace of the patient’s private information. The next step, 
Research and Discovery, has the bio-specimens analyzed. Some characteristics studied include 
how gene expression occurs as well as genome rearrangement.  Data Sharing occurs using this 
information, and it is performed by the TCGA Data Coordinating Center. The data is stored in a 
large public database so that researchers can search for specific cancer type information. After 
searching, scientists can then download and analyze the data. This leads to the final step of 
Community Research and Discovery, the database is open to the public so that the most up to 
date information on cancer genomes are being studied and sent worldwide. This personalized 
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approach allows a specimen from one person to contribute to a large database, where more 
accurate information about data can be further obtained. [6] 
 
2.5.2 Zebrafish Study 
 
One new technology that is making huge strides in cancer research is the use of 
zebrafish as an animal model of human cancer. Zebrafish develop cancer naturally and quickly 
and this is very useful for cancer research. The cancer is established after being exposed to a 
mutagen and through transgenesis, where the genetic material is being brought from a 
different species. One of the biggest reasons why zebrafish are being used as an animal model 
for human cancer is the fact that the tumors formed in a zebrafish have similar characteristics 
to those of human cancers. The genomes of the tumors are comparable, as well as their gene 
expression and their microscopic cell anatomy. The genome for the zebrafish has been fully 
sequenced as well.  This fish can also reproduce at a frequent rate and can produce 200-300 
embryos a week.  Zebrafish are also an excellent model for in vivo imaging. A huge reason for 
this is due to the unique fact that their skin is translucent. Their skin allows us to witness 
tumor growth and actually see if cancer treatments are effective or not. Originally, only 
juvenile zebrafish were transparent, and would lose this characteristic once an adult, when it 
becomes opaque. However, a recent study has allowed this trait to remain when they grow 
into adults. [51]  
 
Figure 11:Transparent Adult Zebrafish [51]. 
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Figure 12: Advantages of Zebrafish based on its lifecycle [51]. 
 
2.5.3 Tissue on Collagen I-Hydrogel Scaffold 
 
A huge issue in cell culture is the fact that cells grown in a 2D environment, such as in 
a petri dish (in vitro), is not an accurate representation of its future performance in an in vivo 
biological system. There has been more of an effort thought to grow cells in a 3D environment, 
in order to receive stimulus comparable to that inside the body. This would allow the cultured 
cells to acquire phenotypes, or observable traits, which would prepare it for in vivo 
placement. This applies to tumors as well. For this study, collage I hydrogels cultured with 
tumor cells was studied in vitro. [52] 
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Figure 13: Collagen I hydrogel cultured with MDA-MB 231 [52]. 
For the cell culture, MDA-MB-231 human breast cancer cell line was used. This study 
mixed breast tumor cells with collagen to make a scaffold, and then studied cellular 
properties. The hydrogel scaffold allows for controlled observation of the tumor cells, since it 
fixes the proteins. It was found that cells that were cultured in collagen I hydrogels for a week 
established typical cell-matrix and cell to cell interactions observed in vivo. These cells also 
exhibited an elongated morphology which is very common for cell-matrix interactions. Once 
the cells began proliferating, they formed three dimensional clumps which showed the cell to 
cell interactions. 
38 
 
 
Figure 14:MDA-MB-231 cells cultured in collagen I hydrogel for a week [52]. 
 
Figure 15: Tumor Necrosis due to Hypoxia [52]. 
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This experiment had issues however. Because tumor cells were being cultured, cell 
proliferation was uninhibited. As cells began growing and forming three dimensional clumps, 
hypoxia became an issue. Hypoxia occurs to the lack of oxygen that cells towards the center of 
a growing tumor has. If hypoxia is not remedied, either by increasing oxygen or removing 
external tissue, necrosis (cell death) occurs. In order to remedy this, the group reduced the 
scaffold’s thickness to increase the oxygen intake. [52] 
 
2.5.4 Scale 
 
 Imaging the neurons and projections of the brain is being studied vigorously, in order 
to fully create and understand the structure of the brain. This has been difficult due to the 
issue of light scattering caused by the lipid bilayer. Scale, an aqueous reagent, is used to make 
biological samples optically transparent and this method allows fluorescent signals to be 
conserved. The reagent is used to make mouse brain and mouse embryos both transparent, 
and this allows the signals to be studied.  
 
Figure 16: Two mouse embryos after fixation, left fixated in PBS and right in ScaleA2 for two weeks 
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 This method of inducing transparency to tissue samples was first discovered by 
accidental observation. Polyvinylidene fluoride membranes became see-through after being 
soaked in 4 M urea. To further improve the transparency, the group optimized and created a 
solution called ScaleA2, which was composed of 4 M urea, 10% glycerol and .1% Triton X-100.  
This solution had to be tested, so it could be compared with other water-soluble reagents. 1.5 
mm thick slices from mouse brain samples were obtained and soaked in five different 
solutions: PBS, 60% sucrose/PBS, FocusClear, MountClear and ScaleA2. Light transmission 
was determined using a spectrophotometer. The slice soaked in ScaleA2 was noticeably more 
permissive to visible and infrared light than the slices soaked in the other reagent. 
 
Figure 17: Light Transmittance of ScaleA2, 60% Sucrose/PBS, Focus/MountClear, and PBS [53]. 
 Even though there was evidence for tissue swelling, after testing, it was found that the 
internal composition of the fixed brain kept their original proportions and form. This suggests 
that the tissue expansion was homogenous and uniform in every direction. Swelling is not 
ideal, so the group then created a new solution. ScaleU2 is composed of 4M urea, 30% glycerol 
and .1% Triton X-100. ScaleU2 does reduce the amount of swelling but it increases the time it 
takes to become transparent. Swelling affect the fragility of the cleared brain samples so this 
is not wanted. ScaleA2 takes a couple of days to weeks in order to make the sample 
translucent but ScaleU2 takes a couples of weeks to even months. Washing the ScaleA2-
treated sample with PBS can shrink it back to original size. 
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Figure 18:Mouse brain before and after ScaleA2 (two weeks) [53]. 
 Scale has the unique capability to preserve the signals of fluorescent proteins, while 
other organic solvent-based reagents removed it. Scale is also inexpensive and creating it is 
fairly straightforward. Because of this, Scale can be mass produced in order to clear larger 
tissue samples. Scale is also customizable due to the fact that its composition can be changed 
depending on what tissue is going to the cleared. The concentration of glycerol can be 
increased so that swelling does not occur as much, as in ScaleU2. Scale is also suitable for most 
light microscopy systems. The solution can furthermore be used for all organs. The main 
drawback however, being that time significantly increases for clearance. This drawback can 
be solved by changing the composition of the reagent nevertheless.  
 
42 
 
 
Figure 19:ScaleA2 steps for tissue transparency for deep imaging [53]. 
2.5.5 CLARITY  
 
 A very pertinent study was performed in Stanford University where a brain was made 
transparent and 3D mapped, in order to study the neural structures. Their goal was to quickly 
convert an intact mouse brain into a transparent and molecule-permeable brain. At the same 
time, basic molecular structure had to be preserved. This was an issue, because lipid bilayers 
on the brain, causes light scattering, thus making imaging next to impossible. The lipid bilayer 
has to be removed in order for light to fully penetrate tissue. This process must occur in a safe 
way so proteins and other material won’t get denatured. Removing the lipid bilayer can affect 
other properties of the brain. This layer retains important molecules such as proteins which 
contains cellular information. The lipid membrane also supports the structure and removing 
this makes imaging difficult. The CLARITY (Clear, Lipid-exchanged, Anatomically Rigid, 
Imaging/immunostaining compatible, and Tissue hydrogel) method is used to make the brain 
transparent and provide a secondary support system after removing the bilayer. [8] 
 The initial step performed by the Stanford group was to take hydrogel monomers and 
formaldehyde and embed them into tissue. The hydrogel monomers, acrylamide and 
bisacrylamide, are used in order to create covalent bonds with important molecules such as 
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nucleic acids and proteins. Formaldehyde is used to crosslink the tissue at a temperature of 
4°C (Figure 20). [8] 
 
Figure 20: Infusion of monomer (blue), formaldehyde (red) and tissue. 
Next, this monomer-tissue is polymerized into a hydrogel mesh by incubating at 37°C 
for 3 hours. The tissue and the hydrogel then become one hybrid construct and this is what 
will be physically supporting the tissue (Figure 21). This construct will also allow important 
molecules such as proteins to remain, after the lipid bilayer gets removed. 
 
Figure 21: Creation of hydrogel mesh by incubation [8]. 
The third step is to get rid of the lipid bilayer. The Stanford team developed a unique 
ionic extraction technique in order to achieve this. This method was chosen over using a 
hydrophobic organic detergent because organic solvents like these quench fluorescence. 
These limits imaging time and this process would also take several months to clear an adult 
mouse brain. The team developed an active-transport organ-electrophoresis method, which 
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they termed Electrophoretic Tissue Clearing (ETC). This technique uses the high charged 
nature of ionic micelles to quickly and actively remove the lipid bilayer (Figure 22). Along 
with a solution, a voltage runs through an ETC chamber to remove the lipids (Figure 23). [8] 
 
Figure 22:Removal of lipids by using SDS detergent and a voltage [8]. 
 
Figure 23: ETC Chamber Diagram [8]. 
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Figure 24: Actual ETC Chamber made from Nalgene Bottle 
The process took eight days to make the intact mouse brain transparent. Using single-
photon microscopy, the sample as imaged and was only limited by the objective’s working 
distance. The brain tissue did expand however there was no deformation. After imaging, 
protein loss of CLARITY is then compared with other reagent based methods after a week of 
clearing (Figure 25): paraformaldehyde (PFA) fixed tissue blocks were cleared by 4% SDS and 
~65% of total protein was lost, the Scale method lost ~41% of protein, PFA-fixed tissue 
treated with .1% Triton X-100 in PBS buffer, lost ~24% of protein, and the CLARITY method 
only had ~8% protein loss. Protein loss means that it will be more difficult to image 
fluorescence, since the fluorescent proteins was removed. 
 
Figure 25: Images of 4 Month Old Mouse Brains.  (A) Before ETC Chamber (B) Scale method for 5 weeks (C) CLARITY 
method for 2 days (D) Fluorescent image of C 
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 This method is significantly faster than the Scale method. It is also better at deeply 
penetrating tissue. One big drawback is when the ETC chamber operates the voltage increases 
the temperature, which is an issue when trying to keep tissue intact. 
 
Figure 26:3D Map of Stained Hippocampus. Blue areas are supporting glia, red areas are connecting interneurons, and 
green areas are fluorescent-expressing neurons [8]. 
2.5.6 SeeDB 
 
 Another method studied using an optical clearing agent, SeeDB (See Deep Brain), also 
retains fluorescent proteins. Most clearing agents do not and this leads to quenching, which 
increases imaging difficulty. A team of Japanese scientists from the RIKEN Institute developed 
this agent, which is mainly made up of fructose sugar and water. By soaking the tissue sample 
in this solution, it will eventually become transparent due to the immersion in SeeDB. This 
solution has been used to get rid of the lipid bilayers of mouse brains and embryos without 
damaging their structural integrity. These lipid bilayers however, cause light scattering, which 
is the biggest issue in imaging. Light scattering is caused by a difference in refractive indexes. 
The refractive index of SeeDB is 1.490 which is very close to that of lipids (fats). The refractive 
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index using a dimensionless number indicates how well light goes through that medium 
(Figure 27). 
 
Figure 27: Refractive index equation. c= speed of light in a vacuum v=speed of light in the substance [54]. 
 SeeDB works by having the solution having a similar refractive index. By soaking in 
the solution, the lipids basically become see-through. SeeDB also does cause shrinkage or 
swelling. The only issue is that when incubated the tissue at higher temperatures, browning 
occurs in the fructose solution but this can be cured by adding α-thioglycerol. ScaleA2 fully 
cleared the adult mouse brain of lipids in 21 days, CLARITY needed 9 days, while SeeDB only 
takes 3 days. SeeDB also causes no change in sample volume, and is completely reversible. 
SeeDB is inexpensive, safe, easy, and relatively fast. 
 
 
Figure 28: Various tissues before and after SeeDB [55]. 
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2.5.7 Supercritical CO2  
 
Supercritical substances are fluids that are brought to a particular temperature and 
pressure. This particular point is referred to as its critical point, and beyond this, attains the 
special property of behaving like a gas and liquid (Figure 29). Supercritical fluids (SCF) can 
dissolve materials like a liquid while also being able to effuse through solids like a gas. [58] 
 
Figure 29: Phase Diagram of Carbon Dioxide (based on Pressure and Temperature) [57]. 
Supercritical fluids have very high diffusion coefficients and can easily remove lipids, 
even better than commonly used detergents. SCF also have a low viscosity so it can expand 
well. For example, a liquid solvent that took hours or days to extract the lipids from a tissue 
could take minutes if the supercritical fluid was used instead. Advantages of this technique are 
that it is cheap, safe, and very effective.  Most organic solvents use toxic solutions, but CO2 is 
not toxic in any fashion. One drawback is that not a lot of data exists on studies performed 
using supercritical carbon dioxide and tissues so all the effects are not readily available. 
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Another is that the mechanism to control temperature and pressure is more complicated than 
other methods. 
 
 
Figure 30: Comparison of supercritical extraction and solvent extraction [58]. 
 
 
 
Figure 31: Supercritical Fluid Extraction Diagram [58]. 
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3.1 Initial Client Statement 
 
The initial client statement provided by the project advisor, Dr. Ming Su, informed the 
group of the possible improvements for cancer therapy, assuming the project is successful. 
The group then organized a detailed literature review in order to understand present 
shortcomings and current products based on the given statement. While expanding our 
knowledge on the issue, the team took note of possible objectives and constraints for the 
project design. After further discussions with the project advisor, who was the client as well, 
the team created a list of functions that the design had to fulfill. This culminated with a revised 
and focused client statement. 
The original statement conveyed by the project advisor, Dr. Ming Su, was: “Tumor is a 
heterogeneous construct. Assessing tumor heterogeneity as part of a diagnostic may help to 
better predict a patient’s potential for response, and provide rationale and selection of 
therapy. This project is to develop a method that allows 3D fluorescence technique to check 
tumor heterogeneity in tissue by making this tissue transparent to visible light. A hydrogel 
scaffold will be generated by ultrasound enhanced diffusion of hydrogel pre-polymer into 
tissue, radiation induced polymerization of pre-polymers, and electrical leaching of non-
transparent lipids. A variety of fluorescence molecular probes will be used to label tumor 
specific proteins, and provide a 3D map of how tumor cells and normal cells are arranged in a 
heterogamous environment.” 
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3.2 Objectives 
 
 After conducting more research, it became apparent to the group what key 
characteristics the final design would need in order to be successful. Key objectives were 
discussed with the client, until a list of six core objectives was created. The final design will be 
adaptable, fast, inexpensive, reliable, safe, and user-friendly. 
 
 
 
 
 
 
 
 For assessment purposes, a pairwise comparison chart was produced, as seen below in 
Table1: 
 
 Inexpensive Adaptable Reliable Fast Safe User Friendly Total 
Inexpensive  0 0 0 0 0 0 
Adaptable 1  0 0 1 0 1 
Reliable 1 1  0 1 1 4 
Fast 1 1 1  1 1 5 
Safe 1 1 0 0  0 2 
User Friendly 1 1 0 0 1  3 
Table 1: Pairwise Comparison Chart 
Transparent 
Tissue Method 
Adaptable Fast Inexpensive Reliable Safe 
User 
Friendly 
Figure 32: Objectives Tree 
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The most important was the “Fast” objective. The two current methods researched, 
CLARITY and Scale, took weeks to fully finish the 3D mapping, even though most of the time 
was spent waiting for the tissue to become transparent. This length of time is not acceptable, 
because it takes too long for a tumor sample to be tested, and this would lead to a delay in 
therapeutic use, regarding what drug should be given to combat the cancer. The second most 
important objective was for the design to be reliable. The process of preparing transparent 
tissue samples has to work every single time. If our design was used in clinical applications 
any errors would cause clinicians to give incorrect advice and thus have the patient suffer 
from drug’s side effects. The process must not be overly complicated as well. The third most 
important objective was that the process has to be user-friendly. We do not want the process 
to be limited to only very technical positions. The fourth most important objective is that the 
method is safe. This means that the toxicity of the reagent used has to be minimized. The 
method of creating the transparent tissue needs to present no hazards as well. The fifth most 
important objective was that it has to be adaptable. The Scale method has the drawback of 
tissue becoming swollen due to the long amounts of time of being immersed in solution.  The 
CLARITY method had the drawback of having the electrophoretic tissue clearing chamber 
becoming warmer as current ran through it. Our design should be able to adapt to these 
changes and provide a counter measure to ensure proper data will be obtained. The least 
important and last objective is that the process has to be inexpensive. Some materials in the 
process must last long enough to be reused. The design has to be relatively cheap to build and, 
further down the line, cheap to run/repair. 
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3.3 Constraints 
 
 Subsequently discussing the objectives with the project advisor, several constraints 
were created in order to shape the design process. The cost of the final design cannot exceed 
$212 because of our project’s budget constraint. The tissue samples that we use to test our 
design on will be obtained from the laboratory itself and will not be purchased. Another 
constraint is time; the team only has until May 1, 2014 for submission of e-CDR. The group 
also needs to create a method that takes a shorter amount of time than the two weeks that it 
took Scale/CLARITY.  Two big constraints that are vital to the design are temperature and pH. 
Temperature needs to remain constant at 37o C. The pH also needs to be regulated, between 
6.5 and 7.5. Outside this range, irreversible damage will occur to the tissue-hydrogel 
construct. When making the tumor tissue transparent, the voltage that runs through the 
electrophoretic tissue clearing chamber would cause the temperature to rise. This needs to be 
limited because it would degrade the tissue sample. For pH, cancerous tissue has a lower pH 
than regular tissue, so adjustments will need to be made, for the varying ranges in pH, for the 
solution. 
3.4 Revised Client Statement 
 
 Develop a cost-effective, time-effective and replicable method that enables tissue 
transparency by supercritical fluid extraction.  This method should provide reliable results 
quickly, maintain structural integrity of the tissue after extraction, exhibit improvement in 
tissue transparency, and minimize toxic byproducts. This method should provide the 
foundation for a future scalable extraction chamber for tissue samples with the goal of 
allowing clinicians to determine and analyze tumor heterogeneity by imaging transparent 
tissue.  
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3.5 Project Approach 
 
3.5.1 Technical Approach 
 
 The first step in creating the design was selecting a hydrogel that would preserve the 
tissue, no matter what stresses occurred to it. Research was performed and hydrogels were 
examined, with the goal of only binding to protein and nucleic acids, and not lipids. These 
lipids need to be extracted and our design had to be extremely efficient, in order to improve 
the biggest drawbacks of current clearing technologies: time. By studying the three different 
clearing methods, a unique method is obligatory in order to satisfy the clearing speed. Testing 
will also be performed prior to tissue experimentation, in order to quantify the procedure.  
 
3.5.2 Design Evaluation Matrix 
 
 A design evaluation matrix was made in order to determine the viability of potential 
design alternatives. The alternative designs needed to meet the following constraints: time 
(about six hours), final cost (less than $212), and temperature/pH/pressure adjustment. The 
objectives which served to compare the alternatives were: fast, inexpensive, user-friendly, 
reliable, safe, and adaptable. A scale from 0-50 was used to compare how well objectives will 
be met among the three preliminary alternatives.  
Design Constraints 
(C) and Objectives 
(O) 
ETC Chamber Supercritical CO2 Optical clearing 
reagent 
Time “<6 hours” (C) no yes no 
Cost “$212” (C) yes yes no 
Adjustable (C)  yes yes yes 
    
Fast (O) 40 50 20 
Inexpensive (O) 30 50 20 
User-friendly (O) 20 30 50 
Reliable (O) 45 40 20 
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Safe (O) 10 50 15 
Adaptable (O) 20 30 50 
Total score 165 260 175 
Table 2: Design Evaluation Matrix 
Based on the total score obtained in the design evaluation matrix, our most favorable 
preliminary design involves the use of supercritical CO2. 
3.5.3 Design Functions and Specifications 
 
 Based on literary research and comprehension of our objectives and client statement, 
the team focused on forming an inclusive list of functions and specifications for our design.  
3.5.3.1 Functions 
 
 For the establishment of functions, the team created a list of tasks that the device must 
be able to do: 
 Function 1: The device must not damage tissue. 
 Function 2: The device must not cause degradation of hydrogel. 
 Function 3: The device must remove lipids quickly. 
 Function 4: The device must contain a solvent. 
 Function 5: The device must allow removal of byproducts after lipid extraction.  
 Function 6: The device must maintain a minimum temperature. 
 Function 7: The device must maintain a constant pH. 
 
 
3.5.3.2 Specifications 
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 Using the functions list as a model, the team created customized specifications for the 
design. The constraints that limit the team are time, budget, pH of tissue, and temperature of 
tissue environment. Based off of these constraints, and adding into account the objectives and 
functions, the team established specifications for the device, which are shown below. This list 
was created to satisfy the specific design needs: 
- Control pH of hydrogel and tissue in the range of 6.5 to 7.5 
- Produce environment with a maximum temperature of about 37°C 
- Maintain original tissue structure after lipid removal  
- Take a maximum of 6 hours to remove lipids 
- Yields a 10% transparency improvement 
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Chapter 4        
Alternative Designs 
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4.1 Needs Analysis 
 
Our team created a list of the needs that the final design needs to cover. To do this, our 
team looked back at the revised client statement. The client statement allowed us to identify 
that our design needed to be time-effective, replicable and efficient. To further clarify the 
needs of our design, our team met on a weekly basis. In these meetings, the team discussed 
the different possible final designs of the project. During these meetings the team came up 
with the list of objectives, constraints, functions, and specifications that were listed in Chapter 
3. Our team then created a Needs Analysis Chart to establish the guidelines that the final 
design had to follow to ease the process of final design selection. The Needs listed on such 
chart are meant to demonstrate the qualities that the final design needs to have in order to 
satisfy our team’s objectives and constraints.  The Wants listed on the chart represent all the 
desired qualities of our final design. The Wants are not considered to be a vital part in the 
final design and can thus be absent from a design choice. The following table shows the Needs 
and Wants used for our design analysis. It also provides a brief description of each Need and 
Want. 
 
Needs Definition 
Adaptable The ability of the design to hold different 
tissue sizes and types (in terms of weight, 
volume, and composition).   
Accurate The ability of the design to yield accurate 
results (in terms of transparency limit). 
Time-effective The ability of the design to perform under a 
specified time limit. 
Safe The ability of the design to effectively 
reduce waste material production, to reduce 
potential hazards inherent to the design 
itself, and to reduce hazards related to 
handling of the device.  
Ease of use The ability of the device to be handled with 
ease. This also refers to the ease in test 
reproducibility. 
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Wants Definition 
Self-regulation The ability of the design to regulate solvent 
flow and inherent design properties (such as 
temperature, pressure, and pH). 
Manufacturability The ability of the design to be easily 
manufactured and reproduced. 
Table 3: Defined Needs and Wants table 
The needs of our design correspond to what the team considers to be the most 
important characteristics of a functional system. For the first two Needs, “Adaptable” and 
“Accurate”, our team valued the idea that the design must yield accurate results. For this to 
happen, the design needed to adapt to the different sizes of tissue samples that were collected 
for testing. The “Accurate” Need told us that the design needed to yield accurate results. This 
implies that the transparency achieved after lipid extraction must be sufficient to be noticed 
by the naked eye.  
The remaining Needs of our design, “Time-Effectiveness” and “Safety”, focus on 
particular aspects of the design instead of focusing on the end goal of the design. The “Time-
Effectiveness” Need was based off of our constraint that the final system must perform under 
six hours. The need to have a safe system takes into account the fact that the lipid extraction 
device should work under minor hazardous conditions. The device needs to work under 
temperatures and pressures that might cause threats if the device is mishandled. Thus, it was 
important to prepare a device that could sustain relatively high temperatures and high 
pressures without presenting much of a hazard to the user. Also, the device must need to 
provide a safe way to get rid of waste products that may arise from the lipid extraction. In the 
best case scenario, the design should reduce toxic waste to zero. The Need “Ease of Use” refers 
to the lack of complexity involved in handling the device. This Need will allow us to determine 
the level of difficulty in operating the final device once it has been built. Ideally, the device will 
not provide a challenge while it is being handled or while the tests are done. 
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The Wants of our design refer to the characteristics that the team desired to include in 
the final device. However, the Wants are not essential for the final device to be considered a 
success. Instead, the wants for this design are characteristics that under ideal conditions will 
be included in the design. The wants for this design are “Self-Regulation” and 
“Manufacturability” and are shown in Table 3.  The “Self-Regulation” Want focuses on the way 
in which the system, specifically the lipid extraction device, will regulate solvents and other 
properties such as temperature and pH.   The “Manufacturability” want refers to the ease of 
fabrication of the device as well as the ease of assembling. It is desired for the device to be 
manufactured using materials that are both inexpensive and readily available.  
 
4.2 Conceptual Designs 
 
 In order to create a device with the required functions, objectives, specifications, and 
constraints, multiple preliminary design proposals were created. Because the two main tasks 
of the design involved the hydrogel and supercritical fluid extraction (SFE) apparatus, 
achieving those tasks became the focus for the conceptual designs. Achievable methods for 
lipid extraction involve the use of a clearing agent, electrical leaching, or supercritical CO2 and 
all three methods can use hydrogel without any issue. 
  
4.2.1 Clearing Agent as a Solvent 
 
 The first conceptual design was based on solvent use. Aqueous reagents are often used 
to make biological samples optically transparent and this method allows fluorescent signals to 
be conserved. By observing studies such as Scale and SeeDB, it was determined that fructose 
and urea are methods of extracting lipids. SDS tissue clearance is also another popular 
method. All in all, these detergents are used to bind to hydrophobic surfaces to extract lipids 
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within tissues. We also proposed a hydrogel system to be used alongside the solvent to bind to 
proteins and nucleic acids and help maintain tissue structure. After the tissue is embedded in 
the hydrogel, immersion into the clearing agent is next. The clearing agent, SDS, Scale, or 
SeeDB, will only remove lipids, because the hydrogel is bound to protein and nucleic acids, 
thus preserving them. This conceptual method is the simplest, only requiring immersion into 
the solution, and removal of sample after certain amount of time.  
 
4.2.2 Optical Clearing through Electrical leaching 
 
 The second concept was based off of Stanford’s CLARITY. A chamber was built based 
off of electrophoretic technology. Electrophoresis is based off of separating molecules through 
the use of an electric field. This method would use the high charged nature of ionic micelles to 
quickly and actively remove the lipid bilayer membrane of cells, with a voltage running 
through an ETC (Electrophoretic Tissue Clearance) chamber. The chamber would also be 
inside an ice bath to help minimize tissue damage caused by the temperature increased due to 
voltage. Our design would be based off of CLARITY and would be improved by incorporating a 
pump that circulates optical clearing solution and filters out extracted lipids. The design 
would also have a mechanism to decrease the temperature increase caused by the voltage, 
and this would enable a higher voltage in order to increase the clearance speed without the 
drawback of tissue damage due to heat.  
 
4.2.3 Supercritical CO2 for lipid extraction 
 
 The last concept is based off a current method of creating perfumes, soaps, and other 
cosmetics []. Supercritical fluids such as CO2 have been used in fruits industries to extract oils 
from fruits and plants. This method would utilize the high diffusivity and low density of 
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supercritical CO2 to only remove the lipids from the tissue. A chamber would be created that 
incorporates a pump system, a cooler, and an oven. The CO2 would flow from the carbon 
dioxide tank and go through the cooler, and then be pumped into the oven, where it becomes 
supercritical due to the increase in temperature and pressure. This method is very 
complicated due the numerous contraptions needed to extract the lipids from the tissue. The 
method itself shows promise in the fastest lipid extraction, and so this was the model for our 
design. However, due to the complexity of the SFE mechanisms that currently exist in 
industry, alternative methods for creating a supercritical fluid were explored.  We found out 
that there were less complicated methods for producing supercritical fluids, and so we based 
our modeling off of one of those methods.  
4.3 Design Modeling 
 
Modeling was done in order to visualize the chosen concept for the design. Computer 
software (Solidworks) was used to create a 3D model of what would later be the design 
schematic for a real life prototype. The computer model was based off of an engineering 
model created by Krasnow for the purpose of oil extraction from various natural products 
(coffee, vanilla, and cinnamon) [60].  Its main components were the upper CO2 chamber and 
the lower extraction chamber. Two caps secured the upper chamber, while one of those caps 
had a pressure gauge attached to it. Two endplates were attached to the extraction chamber. 
The lower endplate had an O-ring in order to prevent CO2 from escaping at the connection 
between the lower endplate and the extraction chamber. Four bolts and four nuts were used 
to hold the endplates in their place.  A valve was connected to the lower cap of the CO2 
chamber to the upper endplate of the extraction chamber.  A second valve was connected to 
the lower endplate. The figures below show the CAD models of the SFE chamber we created at 
the beginning of the project. 
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Figure 33: CAD model of the supercritical fluid extraction chamber. 
  
 
Figure 34: CAD model of the lower extraction chamber. 
After creating the CAD model of the design that the team chose for the SFE chamber, 
the team decided to purchase the materials needed for the SFE chamber from McMaster-Carr. 
The CAD model allowed us to adjust the dimensions of the chamber based on the model 
developed by Krasnow and the needs of our design outlined in the Needs Analysis Section 
[60]. Below is a list of all the materials we required to build the initial SFE chamber: 
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Item  Specification 
Acrylic column 2.50” x 4.00” (OD x H) 
3/4” (center hole) 
Aluminum endplates 4” x 4” x 3/4” (L x W x H) 
3/8” (bolt hole D) 
½” (center hole D) 
2.50” (o-ring OD) 
Schedule 80 steel pipe nipple 3.00” x 10.00” (D x H) 
2.25” (hole D) 
External thread 
Steel caps 3.50” x 2.00” (D x H) 
3.00” (hole for pipe D) 
1/2” (hole for valve D) 
¼” (hole for pressure gauge) 
Internal thread 
3/8” Bolts 1/2” (Side of hexagonal head) 
3/8” x 6.00” (D x H) 
External thread 
Nuts for 3/8” bolts 1/2” (Side of hexagonal head) 
1/2” (H) 
3/8” (center hole D) 
Valves 1/2” (OD) 
External Thread 
Pressure gauge 1/4” (OD) 
External thread 
O-ring 15/16” (ID) 
1 3/16” (OD) 
Table 4: Specification table for the materials used to build the SFE chamber. 
In addition to the materials used for the SFE chamber, a few other materials let us put 
the SFE chamber together and run the extraction. Military grade tape was used to prevent 
leaks.  A blowtorch using propylene as its fuel was used to heat up the upper CO2 chamber. 
Heating tape was used on the bottom valve to maintain heat as CO2 escaped through that 
valve. A wrench was used to tighten connections, whereas a small duty vise was used to hold 
the entire chamber onto a table. 
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4.4 Feasibility Study 
 
Once the prototype SFE chamber was built, a few tests were done to ensure that it 
would meet most of the needs developed in the Needs Analysis section. These tests were done 
to assess that the SFE chamber was capable of keeping CO2 beyond its supercritical properties 
and to assess the lipid extraction device’s ability to properly extract lipids.     
First of all, we assessed for proper assembly and leaking. To do this, the team 
assembled the SFE chamber for the first time as shown Figure 35. In order to see if the 
chamber could reach the supercritical CO2 minimum pressure, dry ice was packed inside the 
CO2 steel chamber. This chamber was then heated with the blowtorch until the pressure 
needle on the pressure gauge went past 1100 psi. Since thermocouples were not available in 
this project, temperature readings were done by attaching an instant-read needle 
thermometer to the side of the CO2 chamber. In order to check for potential leaks at the 
different connections of the entire SFE chamber, we identified leaks using our fingers to feel 
for escaping gas. Plus, the condensate of water that formed as air hit the chamber helped us 
see the leaks as bubbles formed when the water droplets hit the connections of the chamber. 
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Figure 35: Assembly of the SFE chamber. 
Second, we did another feasibility test to determine if our SFE chamber was capable of 
extracting oils from fruits. From our research we found that SFE on fruits such as oranges or 
vanilla yields oils that vary in quantity based on the pressure and temperature conditions 
used in the extraction. The setup for our extraction was also based on Krasnow’s setup [60]. 
The setup consisted on placing dry ice in the CO2 chamber, sealing the chamber, and heating it 
up until the pressure was above 1100 psi. At a certain point, the temperature was also 
measured to make sure that it had gone beyond the critical temperature of CO2. Prior to 
heating the chamber, the fruit samples were cut in small pieces and were put in the extraction 
chamber.  Having placed the sample in the extraction chamber, we proceeded into heating the 
CO2 chamber. After the temperature and pressure had reached the critical properties of CO2, 
we opened the lower valve. A small glass beaker helped us collect the extract we obtained 
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from the samples. It is important to note that there was an adjustment made after the vanilla 
samples were used. The acrylic used for our extraction chamber was very prone to being 
dissolved by the supercritical CO2. So, after we opened the upper valve on the extraction 
chamber for one of our extraction tests, the acrylic chamber burst. This made us change the 
way in which we did future extractions. From then on, the orange samples were placed in the 
CO2 chamber along with the dry ice until we decided to start testing SFE on tissue.  
To determine the identity of our extract we used a UV-Vis spectrophotometer 
technique. From our literature, we found the absorbance properties of limonene (orange oil’s 
industrial name). We set the baseline in the spectrophotometer using dH2O. We then mixed 
some of our orange extract with dH2O, placed this solution into a cuvette and then into the 
spectrophotometer slot. The cover of the device was closed and the software was set for the 
analysis. The software of the spectrophotometer was set up to take absorbance values 
between 200nm and 340nm. After making sure that all was in place, we ran the 
spectrophotometer. The resulting absorbance values are presented in the next section. 
 
4.4.1 Preliminary Data  
 
Our preliminary data was obtained after assessing the capacity of our SFE chamber to 
extract oils from fruits while maintaining CO2 in its supercritical state. For our assembly tests, 
we assessed whether or not our chamber could reach the supercritical properties of CO2. For 
our extraction tests, we attempted to collect oils from the fruit samples in order to determine 
if our design was capable of extracting lipids from fruits. 
There were several observations made for the SFE chamber assembly after loading it 
with CO2. First of all, the SFE chamber did allow for the CO2 to go to a supercritical state. For 
all the extractions, the temperatures reported were between 31°C and 40°C. Unlike the 
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temperatures, the pressures varied for each extraction. For the extraction using vanilla 
samples, the highest pressure that the SFE chamber reached was 1100 psi. Rupture of the 
acrylic chamber occurred at that pressure. For the subsequent extraction using orange 
samples, the pressure went as high as 1400 psi. Leaking always seemed to occur but with 
varying degrees. The most leaking occurred at the connection between the lower cap and the 
CO2 chamber. 
As for the extraction of oils from the fruits, there were several results obtained after 
doing extractions. For the vanilla samples, there was a little amount of extract collected and so 
no analysis was done over that extract. For the orange samples, a considerable amount of 
extract was obtained in the order of about 5mL-10mL. In order to analyze the composition of 
this extract, we collected the sample and did UV-Vis spectrophotometry analysis on it to take 
absorbance values and compare them to the known values of limonene.  
 
Figure 36: UV-Vis absorbance spectra of the extract obtained from the orange samples. The original absorbance plot is 
on the left, while the smoothed absorbance plot is on the right. 
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As illustrated in Figures 36 and 37, the UV-Vis absorbance values of the sample 
appeared very similar to the known values of limonene. The differences between our UV-Vis 
values and those from the reference limonene are due to (1) the wavelength used to measure 
the absorbance values for our sample, and (2) possible impurities that were in our extract. 
 
4.5 Final Design 
 
The final design for a SFE chamber device chosen by the team consisted of the 
following main components: a CO2 chamber, an extraction chamber, valves to regulate flow, a 
thermometer and a pressure gauge, and a heat source in the form of a blowtorch. The CO2 
chamber was made of a Schedule 160 steel pipe after determining that the maximum pressure 
of the previous Schedule 80 steel pipe remained unknown after contacting the suppliers. The 
Schedule 160 steel pipe is known to support pressures up to 3000 psi in room temperature 
and was thus a safer choice. Two high density steel caps were tightened at the end of the steel 
pipe to seal the chamber. The extraction chamber was changed from the acrylic one to a 
stronger aluminum chamber. The extraction chamber was held by two aluminum endplates 
Figure 37: UV-Vis spectra of the reference limonene. 
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which were held by four bolts and four nuts. Valves were placed on the connections between 
the CO2 chamber’s lower cap and the extraction chamber’s upper endplate, and on the 
extraction chamber’s lower endplate. The SFE chamber thus allowed for a blowtorch to heat 
up the CO2 chamber until CO2 became supercritical. The valves then regulated the flow of 
supercritical CO2 from the CO2 chamber into the extraction chamber and from the extraction 
chamber into a glass beaker. All of the final design’s components and their specific dimensions 
and properties are shown in the Appendix.  
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Chapter 5      
Methodology (Design Validation) 
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After assessing the properties of our preliminary design through our feasibility tests, 
we decided that the concept of SFE was feasible to be used for lipid extraction in tissues. 
Furthermore, we also managed to design a SFE chamber that extracted oils from fruits. These 
preliminary results gave us proof that SFE using CO2 was going to prove useful in extracting 
lipids from tissue. Thus, our team decided to prepare a set of procedures in order to test our 
design’s efficiency in removing lipids from tissue.  Just as with the initial design, we decided to 
do extractions while measuring the temperature and pressure on the CO2 chamber to 
determine if supercritical conditions for CO2 were met. We also decided to incorporate a 
hydrogel scaffold into our design in order to maintain tissue integrity while undergoing 
extraction. We decided to do this because of the potential of high pressures in the chamber to 
damage the tissue.  Finally, after running several extractions we decided to assess changes in 
transparency in tissue by observing them against a patterned background. As will be later 
explained, this was done to observe the differences between tissue samples prior the 
extraction and tissue samples after extraction.  
5.1 SFE Chamber  
 
Asides from the materials previously used in the feasibility tests, a new set of 
materials were needed for tissue lipid extraction. After looking at the results from the 
feasibility tests, the team identified a few changes to be made to the SFE chamber in order to 
extract lipids from tissues effectively.  From our previous tests, we knew that the acrylic 
chamber had to be substituted for a stronger material that could resist higher pressures for a 
longer period of time. We decided to purchase an aluminum rod, machine it, and use it as our 
extraction chamber because of its stronger temperature and pressure properties. Once the 
aluminum chamber was incorporated into our SFE chamber assembly, we obtained the tissue 
that was going to undergo the extraction. We acquired porcine liver tissue and cut it to sizes 
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small enough that allowed us to put them into the aluminum extraction chamber. As we did 
extractions, we determined that varying tissue sizes would allow us to obtain more or less 
extract. For this reason we decided to cut tissues with thicknesses ranging from 5 mm to 1.5 
cm.  
5.2 Hydrogel Scaffold 
 
The porcine liver tissues were embedded on a hydrogel scaffold that would maintain 
integrity of tissues as supercritical CO2 extraction occurred. The complete protocol of 
hydrogel preparation can be seen on the Appendix. Briefly, 100mL of a Hydrogel Monomer 
Solution consisting of 4% Acrylamide, 0.05% Bisacrylamide, 0.25% VA-044 Initiator, 16% 
PFA, 1X PBS, and dH2O was prepared and stored at -20°C. The liver tissue was then placed 
into the solution. The tissue-hydrogel solution complex was then incubated at 4°C for 2 days 
to allow diffusion of the hydrogel solution into the tissue. After incubation, the hydrogel 
solution was degassed to replace oxygen with nitrogen. Next the tissue was incubated at 37°C 
for three hours. After this period had passed, the hydrogel polymerized and formed a gel. The 
tissue-hydrogel samples were then extracted from the gel. These samples were then washed 
with a Clearing Solution made of 200mM Boric Acid, 4% SDS, and dH2O for 24 hours. This was 
repeated two times before the samples were taken out and prepared for extraction. [61]  
 
5.3 Supercritical Fluid Extraction Setup 
 
The team used various unique tests in order to measure the reliability of the device in 
comparison to the methods of CLARITY, Scale, and SeeDB. Three tests were performed and 
they were: 
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• Pressure testing: to determine if the supercritical pressure of 1071 psi was reached. 
• Temperature testing: to determine if supercritical temperature of 31°C was reached. 
• Leakage testing: to determine that no supercritical fluid was escaping the chamber. 
 
For all of the three different types of testing, the final design was used. These tests were 
selected based on optimization parameters in order to extract the most lipid contents within 
the fewest time period.  
 
5.3.1 Pressure test  
 
 In order to measure the reliability of the procedure, a pressure gauge was purchased 
and installed in order to accurately measure the pressure. Pressure drops occurred due to 
supercritical fluid constantly escaping and so heating was performed regularly to maintain 
the desired pressure. 
5.3.2 Temperature test 
 
 To measure if the supercritical temperature of CO2 was reached, a digital probe 
instant-read thermometer was used to reliably check the temperature of the CO2 chamber. 
The thermometer was vertically placed directly on the SFE chamber, and held until 
temperature stopped fluctuating. 
5.3.3 Leaks test 
 
 In order to maintain an efficient lipid extraction, pressure had to be constant. If the 
pressure decreased it would be due to a leak. Therefore, two tests were performed to check 
for leaks. The first one was manual and involved checking with our fingers for any trace of 
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leakage on the connections of the CO2 chamber. If a leak occurred, it would be felt due to the 
tiny bursts of gas escaping the chamber from the bottom. The second, more accurate, test was 
performed using a liquid. Because the holding chamber was very cold prior to heating, it 
formed condensation on the outside. Once heated, this condensation dripped down to the 
lower connection of the CO2 chamber. If bubbles were observed at this spot, leaking would be 
confirmed. These two tests were the only tests that could be performed.  
 
5.4 Experimental setup  
 
 After the hydrogel was removed from the Clearing Solution, excess hydrogel was 
removed and discarded. A picture of the tissue was taken and the tissue was then placed 
inside the SFE chamber. A copper mesh filter was placed right below it to prevent the tissue 
from being expelled through the lower valve. Dry ice was then obtained and placed inside the 
CO2 chamber, and hammered in to fill in all the empty space. The chamber was then 
immediately closed once filled, and heated up with a blow torch until supercritical pressure 
and temperature was reached. The first valve below the lower cap of the CO2 chamber was 
opened to allow the supercritical fluid to enter the extraction chamber. The CO2 chamber was 
then reheated to bring the pressure back up to the supercritical point. This was performed 
due to the drop in pressure caused by allowing the fluid to enter the clearing chamber. For our 
project, we decided to run two different extractions, after 45 minutes and 3 hours. After the 
designated time, the second valve is opened to allow the supercritical fluid to escape. A 
container in the form of a metal bucket was used to collect the lipid extract. After all the 
supercritical fluid has been allowed to escape, the chamber was disassembled and the tissue 
was collected.   
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5.5 Transparency Assessment 
 
After doing extraction on tissue using our SFE chamber, we collected the tissue 
samples and observed them to determine transparency. To do this, prior to doing extraction, 
we prepared a patterned paper that would help us see any differences in tissue transparency 
more easily. The first patterned paper we created consisted of twelve rectangular boxes 
arranged in a 4 x 3 array (rows x columns), where each rectangle was either white or black, 
yet no two neighboring rectangles had the same color. The length of the rectangles on this 
patterned paper was about 15mm and their width was about 10mm. The second patterned 
paper consisted of a pattern of vertical lines with equal spacing between them of about 5mm. 
This second patterned paper had thinner lines of about 3mm wide and was with the smaller 
pieces of tissue.  
The tissue samples were collected after the extraction was run as described in the 
Experiment Setup section. The tissue samples were then placed on top of a glass dish. 
Patterned paper was then placed under the glass that held the tissue. The first type of 
patterned paper was used for the larger tissue samples, whereas the second type of patterned 
paper was used for the smaller tissue samples. Several pictures of the tissues with the 
patterned background were taken. These pictures were then organized and paired by having 
“Before extraction” and “After extraction” images of the same sample. The degree of 
transparency was then assessed qualitatively only by comparing the change in color in tissues 
before and after undergoing supercritical CO2 extraction. 
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This section outlines the results from the experiments with our SFE chamber. 
Preliminary results are shown in order to compare and contrast the UV-Vis spectra of the 
orange extract we obtained in our preliminary studies and the spectra of the known reference 
limonene. This section also shows the results for the degree of transparency of tissue from 
two significant extractions.  
6.1 Absorbance Test Results  
 
Our team obtained an absorbance plot after collecting the extract from the preliminary 
studies using oranges. This was done utilizing a UV-Vis spectrophotometer available at the 
lab. The results of the UV-Vis analysis helped us determine the identity of the extract we 
obtained from the oranges. The plots shown in the spectrophotometer software were 
smoothed to reduce noise. One of the filtered plots was then compared with a plot that shows 
the known absorbance values of limonene. The Figure below shows the two plots. 
 
Figure 38: Absorbance plots for the orange oil extract obtained in our experiments (left) and the reference limonene 
(right). For the plot of the reference limonene, the reference limonene absorbance graph is represented by the solid 
black line. 
Figure 38 shows that the overall shape of the graphs is similar. The absorbance values 
of our oil extract were higher overall throughout all wavelengths. This is attributed to the fact 
that the oil we extracted was not purified before sampling in the UV-Vis spectrophotometer. 
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6.2 Results on SFE Chamber extraction  
 
These images were obtained at different time intervals using the high definition 
camera of a smart phone. In Figure 39, the upper two are representative of the before and 
after porcine liver samples were cleared. The thickness was found to be 15 mm and extraction 
occurred for 45 minutes.  In Figure 39, the lower two are representative of the before and 
after porcine liver samples were cleared. The thickness was found to be 5 mm and extraction 
occurred for 3 hours.  
 
Figure 39: Porcine liver samples before and after extraction. 
After supercritical extraction for 45 minutes, the 10 mm sample showed a 5% increase in 
transparency. This transparency was shown around the edges of the porcine sample and was 
not significant. However, after supercritical extraction for 3 hours, the 3 mm sampled showed 
a 40% increase in transparency. Tissue sample was reduced and supercritical fluid exposure 
time was increased. These factors contributed to such a drastic change in transparency. 
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The various results obtained in our experiments allowed us to make observations on 
the effectiveness of supercritical CO2 in removing lipids from tissue. Our research initially 
suggested that Supercritical Fluid Extraction (SFE) was an advantageous method in lipid 
extraction. Since it is a common method utilized in the food industry to extract oils and resins 
from fruits and plants, it only followed that we did experiments on lipid extraction in animal 
tissue to assess supercritical fluids’ effectiveness in dissolving lipid material. Our preliminary 
results helped us to determine that the SFE chamber we designed worked well. In fact, it was 
through the data acquired in these preliminary experiments that we were able to make 
changes to the design for the subsequent lipid extraction from animal tissue. The results 
obtained from the extractions done on tissue prove that lipid extraction via SFE is a feasible 
alternative option to current lipid extraction methods. 
The preliminary data gathered from the feasibility studies showed that our SFE 
chamber initial design was not capable of maintaining pressures as high as CO2 critical 
pressure. Though leaking issues with our chamber were quickly addressed by securing 
connections with military grade tape, issues with the pressure had to be solved differently. 
The initial component of the CO2 chamber, the Schedule 80 steel pipe was not rated to have a 
maximum pressure. And so the team decided to purchase a rated steel pipe having a 
maximum pressure beyond what was needed for the extraction. Also, the initial acrylic used 
as the extraction chamber ruptured after the third extraction attempt using vanilla beans. This 
burst might have happened after continuous extractions by the supercritical CO2 dissolved the 
acrylic chamber. We believe that the imperfection that the acrylic chamber had after being 
machined at the lathe caused micro-ruptures in the acrylic chamber that later facilitated CO2 
to diffuse through the chamber. Thus, the acrylic chamber was changed in favor of a stronger 
aluminum chamber for the final design.   
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The preliminary data for the oil extract we obtained from the oranges showed us that 
its composition was very similar to the natural orange oil, limonene. These data revealed that 
the absorbance values of our extract resembled the absorbance values of limonene in a 
significant way. Though the absorbance plot obtained from the UV-Vis software was not 
identical to the reference absorbance plot, the shape of the plot provided enough evidence to 
conclude that our extract was composed of lipid material.   
The design was successful in that our goal of improving the transparency of the 
porcine tissue sample was accomplished. The original objective was a 10% improvement but 
we believe the chamber was more efficient and that an improvement of 40% was actually 
reached. However, the tissue sample was not as transparent as other methods such as 
CLARITY. The only pictures available for comparison in CLARITY, Scale, and SeeDB generally 
comprised of a “before” and “after”. Because none of these methods had images after 45 
minutes, or 3 hours, there was no legitimate way to directly assess the effectiveness of our 
chamber. However, we believe our chamber does not take as long as two weeks to clear tissue 
due to the 40% improvement which was performed in under a day, a fraction of the time 
compared to 14 days. The complexity of our design was between CLARITY’s intricate 
procedure and Scale/SeeDB’s simple method. CLARITY created a customized chamber that 
uses electrophoresis to remove lipid, and voltage was administered throughout the tissue 
within a solution. This solution had to be replaced over time in order to remove the lipid 
extracts from the clearing solution due to the reduction in clearance effect. Scale and SeeDB 
were relatively simple due to the fact that the tissue was only immersed in a solution. Scale 
was placed in a urea-based solution and SeeDB was placed in a fructose solution. Both of these 
were incubated in a solution and agitated, and the solution did not have to be replaced.  Our 
design was in between these approaches difficulty-wise due to the fact that we had to place 
dry ice into a chamber and manually heat it, but we did not have to run it for too long. Because 
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it was relatively fast to obtain results, it was a simple procedure due to lack of maintenance 
required. 
                When it came to creating a design, each of the three current methods of removing 
lipids was scrutinized. The biggest drawbacks for each were examined and it was found that 
for CLARITY, 8% of total protein was lost. This is a huge downside because this would affect 
fluorescent staining. All of the proteins are not conserved, and so when imaging occurs, the 
visual representation would not be accurate. CLARITY has the least total protein loss, with 
Scale having a 41% loss. Scale also has issues with maintaining structural integrity. Swelling 
occurs every time, and to decrease swelling, incubation time must be increased to 6 months to 
prevent any swelling at all. After fluorescent staining, this creates flawed imaging as well. 
SeeDB has the drawback of having browning occur, which is due to the fructose. All of these 
drawbacks led to us creating a different method of inducing transparency. Supercritical CO2 
became the desired method for our team not only because of the lipid extraction strength and 
efficiency, but also because of the complexity of current systems becoming an issue. We 
decided to use dry ice instead of complex pumps and tanks due to our budget and time. Dry 
ice is just condensed, solidified carbon dioxide, and we only needed to heat it to create our 
desired supercritical fluid. Dry ice was also relatively cheap in bulk, and could be broken into 
tiny pieces to fit inside our chamber.  
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Chapter 8         
Conclusions and Future 
Recommendations 
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The results obtained in our experiments show that our SFE chamber has potential to 
be used as a model for lipid extraction from tissues. In the feasibility studies, our device was 
capable of removing oils from orange peels. These oils also proved to be similar to the oil 
known to be extracted from oranges in industries. In the experiments done with porcine 
tissue, our device successfully managed to extract lipids while keeping the tissue almost intact 
after extraction. Nonetheless, our team experienced challenges when running the 
experiments. Examples include the acrylic chamber bursting during preliminary testing, the 
leaking caused by improper tightening, and the constant heating of the CO2 chamber. Even 
though some issues arose with regards to the assembly itself, the device showed great efficacy 
by making tissue transparent at almost 40% according to our advisor. Regardless of the 
success of the project, the team identified a few ways in which the concept tested in our 
project can be up-scaled possibly used in clinical applications in the future.  
8.1 Add Heating system 
 
 To reach the critical temperature of CO2, our team heated the SFE chamber with a 
propane blow torch. Heating the CO2 chamber this way took quite some time. Due to the 
concentrated heat being applied to one point of the SFE chamber, temperatures inside the 
chamber must have varied. It is suggested that a self-controlling heating tape be wrapped 
around the chamber to equally heat the CO2 chamber. This heating tape would maintain the 
heat constant throughout the chamber. This would also allow the chamber to be left alone for 
long periods of time which would allow for longer extractions and better results. This heating 
tape would need to be strong enough to heat up a Schedule 160 steel pipe. This would work in 
conjunction with a system for replenishing the dry ice. 
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8.2 Incorporate self-refilling dry ice 
 
 A huge drawback of our design was the relatively short amount of time that the SFE 
chamber was active. A person also had to be constantly reheating the chamber every five to 
ten minutes due to the loss of pressure caused by leakage. The leakage was caused by the fluid 
bypassing the wrapping tape used to cover the pipe threads. If leaking cannot be prevented, a 
system is needed that would enable more dry ice to be placed inside the chamber. This would 
compensate for the escaping fluid because more supercritical fluid would be created. The 
mechanism needed would be spring-loaded and it would need to sense when the pressure 
cannot rise anymore. If the pressure could not go up any higher, then it would be because 
there would be no carbon dioxide left in the chamber. The spring-loaded system would then 
add in more dry ice.  
8.3 Improve Closing mechanism 
 
 The current design is based off a Schedule 160 pipe with external threads caps. The 
threaded ends of the pipe were wrapped in tape in order to help create a tighter fit before 
screwing the caps to the pipe. Once caps and pipe were assembled together, we observed that 
no matter how much tape was used, leaking always occurred. Supercritical CO2 has a high 
diffusivity and low density, so it should be able to tear through the tape quite easily. However, 
we had to prevent as much leaking as possible. A better system would use a vacuum based cap 
that would only get tighter as the higher the pressure rises. This cap would tighten the higher 
the pressure is. It would allow the possibility of air to be vacuumed out of the chamber. This 
would enable more CO2 particles to fit into the chamber and maximize extraction efficiency. 
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8.4 Expand SFE chamber 
 
 Tissue sample size was decreased in our design, in order to improve extraction results. 
Another option however is to increase the size of the extraction chamber, which would also 
improve clearance efficiency. Larger samples could be placed inside the chamber, and 
possibly whole-tissue samples. Enabling lipid extraction in large scale SFE chamber could 
then improve the overall efficiency of the design in making tissue transparent. 
8.5 Implementing Fluorescent Staining 
 
 Ideally our design would need to be able to extract lipids out of tissue that would allow 
for whole tissue staining using fluorescent probes. By making tissue transparent we would be 
able to allow light to go through the entire sample. This would then allow us to incorporate a 
fluorescent tagging technique to visualize the proteins within the tissue sample. If this is the 
case, then different molecules could be tagged with different colors thus allowing for proper 
identification of the molecular composition of the tissue. 
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Cost Analysis (For ETC) 
Item  Estimated Cost Description 
Scaffold fabrication-Scaffold 
material 
$30-$100 Cost based on acrylamide 
monomers pricing. 
Scaffold fabrication-
Crosslinking agent 
$30-$50 Cost based on formaldehyde 
pricing. 
Scaffold fabrication- Tumor 
tissue 
$400-$500 Cost based on mouse and 
human tissue lines. 
Optical clearing method- 
Chamber materials 
$20-$40 Cost based on the pricing of 
materials needed to build the 
ETC (Nalgene, platinum wires, 
epoxy, aluminum) 
Optical clearing method- 
Supercritical CO2  pump 
$3000 Cost based on the ISCO SUPREX 
SCF Extraction Pump 
Optical clearing method-
reagent/solvent 
$65-$120 Cost based on the SDS reagent 
pricing 
Imaging-antibodies $300 Cost based on antibodies from 
Sigma Aldrich 
Imaging- microscope $0 Microscope equipment is 
already in the laboratory 
Prototyping-Rapid prototyping 
model 
$30 Cost based on the estimation of 
the cost associated in building a 
small prototype  
Prototyping- Actual prototype  $70 Cost based on the pricing of 
materials needed to build the 
chamber 
Expected cost of design $85 Based on modification on the 
actual prototype 
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Hydrogel Preparation Protocol 
Hydrogel Materials 
 40 mL of Acrylamide (40%), with final concentration of 4% 
 10 mL of Bisacrylamide (2%), with final concentration of 0.05% 
 40 mL of 10X PBS, with final concentration of 1X 
 100 mL of PFA (16%), with final concentration of 4% 
 210 mL of dH20 
 1 g of VA-044 Initiator, with final concentration of .25% 
Creates 400 mL of hydrogel monomer solution. 
Everything must be kept on ice, store at -20 C until ready to be used.  
Place the tissue in cold hydrogel solution, on ice until it can be moved to a 4°C refrigerator. 
Incubate at 4°C for 2-3 days to allow for further diffusion of the hydrogel solution into the tissue. 
Hydrogel Embedding 
1. De-gas solution (in container) in a fume hood, to replace oxygen with nitrogen (oxygen 
prevents hydrogel formation) 
 Place container in fume hood, and open container to allow gas exchange 
 Turn on nitrogen tank, and adjust control valve so the inlet to the fume hood fills with 
nitrogen 
 Switch the fume hood valve from nitrogen gas flow to the vacuum 
 Turn on the vacuum pump, and allow it to run for 10 minutes 
 Turn off vacuum and slowly turn the valve to fill the chamber with nitrogen 
 Carefully open the chamber just enough to reach the tubes while purging with nitrogen 
gas. Taking great care to minimize exposure to air, and quickly and tightly close the sample 
container.  
2. Place container in 37oC water bath, or incubate it. This must be done for 3 hours until 
solution has polymerized.  
3. In a fume hood, extract the embedded sample from the gel, using gloves. 
4. Wash samples with 50 mL of “Clearing Solution” for 24 hours at room temperature to get 
rid of extra PFAS, initiator, and monomer. This is repeated two more times.  
 
Clearing Solution Materials 
 123.66 g of Boric Acid, with final concentration of 200 mM 
 400 g of Sodium Dodecyl Sulfate (SDS) with final concentration of 4% 
 dH20 is added until 10 L mark 
 NaOH is added until pH is at 8.5 
This creates 10 L, which is 10,000 mL. We only need 150 mL (3 times of washing sample).  
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CAD Drawing of Cap of the CO2 chamber 
 
CAD Drawing of the bolts used to hold endplates of the extraction chamber 
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CAD Drawing of the CO2 chamber 
 
CAD Drawing of the endplate of the extraction chamber 
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CAD Drawing of the extraction chamber 
 
Final CAD model of the SFE chamber assembly 
 
